Regarding the efficacy of anti-interleukin-5 biologics in COPD, which statement is TRUE? a. Both ben

Regarding the efficacy of anti-interleukin-5 biologics in COPD, which statement is TRUE? a. Both benralizumab and mepolizumab are associated with a lower annual rate of moderate to severe exacerbations compared with placebo in COPD with eosinophilia. b. Both benralizumab and mepolizumab consistently improved lung function and quality of life compared with placebo in severe, refractory patients with COPD. c. Benralizumab and mepolizumab show inconsistent effects on exacerbation reduction compared with placebo in patients with COPD. d. Neither mepolizumab nor benralizumab has been adequately studied in phase 3 trials in COPD, just asthma.

******CLICK ORDER NOW BELOW AND OUR WRITERS WILL WRITE AN ANSWER TO THIS ASSIGNMENT OR ANY OTHER ASSIGNMENT, DISCUSSION, ESSAY, HOMEWORK OR QUESTION YOU MAY HAVE. OUR PAPERS ARE PLAGIARISM FREE*******."